Paysign, Inc. (NASDAQ:PAYS) Q4 2022 Earnings Conference Call March 21, 2023 5:00 PM ET
Company Participants
Mark Newcomer - Chief Executive Officer
Jeff Baker - Chief Financial Officer
Conference Call Participants
Gary Prestopino - Barrington Research
Peter Heckmann - D.A. Davidson
Jon Hickman - Ladenburg Thalmann
Operator
Hello and welcome to the Paysign Fourth Quarter and Year End 2022 Earnings Conference Call and Webcast. As a reminder, this conference call is being recorded. This call may include comments that maybe deemed to be forward-looking statements under federal securities laws and the company intends that such forward-looking statements be subject to the Safe Harbor created thereby. All statements beside statements of fact included on this call are forward-looking. Such forward-looking statements include, among others, that we are pleased with the opportunities that lie ahead for us in 2023; our belief that 2023 is looking to be an exciting year across all of our product lines; and our belief that we are all well prepared to capitalize on new opportunities; our plans to continue to add new plasma centers; and our belief that the increasing demand for plasma by the medical industry will facilitate the increase in donations and fuel the continued growth of our plasma businesses; our belief that we are beginning to see real traction in our pharma copay business where we have built an industry reputation of providing reliable patient affordability programs to pharmaceutical companies; our expectation for total revenues, plasma revenues, new centers, pharma revenues, gross profit margins, operating expenses, expected legal expenses for our outstanding litigation, depreciation and amortization, stock-based compensation, interest income, net income, net income per diluted share, adjusted EBITDA and adjusted EBITDA per diluted share for full year 2023; our expectations for total revenue, gross profit margins, operating expenses and adjusted EBITDA for the first quarter of 2023; our belief that inflationary pressures for food, gasoline, rent and other products and services appear to be driving individuals back into plasma donation centers; and our inability to estimate with reasonable accuracy, COVID-19’s further impact on our results of operations, cash flows or financial condition. We caution that these statements are qualified by important risks, uncertainties and other factors that could cause actual results to differ materially from those reflected by such forward-looking statements.
Such factors include, among others, the ability to continue our current growth rate in future periods that a downturn in the economy, including results of COVID-19 and variants as well as further government stimulus measures, could reduce our customer base and demand for our products and services, which could have an adverse effect on our business, financial condition, profitability and cash flows; operating in a highly regulated environment, failure by us or business partners to comply with applicable laws and regulations; changes in the laws, regulations, credit card association rules or other industry standards affecting our business; that a data security breach could expose us to liability and protracted and costly litigation and other risk factors set forth in our Form 10-K for the year ended December 31, 2022. Except to the extent required by federal securities laws, the company undertakes no obligation to publicly update or revise any statements from this conference call whether as a result of new information, future events or otherwise.